Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders
Shots:
- Exicure to receive a $20M up front and will be eligible to receive ~$1B in option exercise fees and milestones along with royalties- if Ipsen exercises its option
- Exicure will be responsible for the discovery and pre-clinical development activities while Ipsen will lead further development and commercialization of the licensed product after exercising the option
- Ipsen obtains exclusive options to license SNA based therapeutics for Huntington’s disease and Angelman syndrome based on two collaboration programs
to | Ref: Ipsen | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com